Stage
No active trials
Next date
None yet
Trials
0 active
2 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Type 2 Diabetes
- Main trialPhase 1
- “A first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE63-0302 administered orally in healthy volunteers.”In the company’s words, NCT06780124 on ClinicalTrials.gov
Other drugs for Type 2 Diabetes
- BR1019Boryung Pharmaceutical Co., Ltd · Phase 3
- CagriSemaNovo Nordisk · Phase 3
- QLG1091Qilu Pharmaceutical · Phase 3
- SHR-3167Hengrui · Phase 3
- Maridebart cafraglutideAmgen · Phase 3
- LenbelintideAstraZeneca · Phase 3
Coming up0
No dates coming up.
Changes1
Last 90 days- 10 NovStatus changed: Active, not recruiting to Completed · ClinicalTrials.gov NCT07234864
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Completed | 24 Jun 2025 | Сlinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of ZE63-0302 in Healthy Volunteers | |
| Phase 1Completed | 21 Apr 2026 | Study to Assess Safety, Tolerability, PK, and PD of Multiple Doses of ZE63-0302 Administrated Orally in T2DM Patients. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026